Last updated on Sunday, 21 April 2019

Christus St Vincent Regional Cancer Center

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NSABP B-51Breast AdjuvantOpen Active2017-01-24NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1207Breast AdjuvantOpen Active2018-10-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2018-09-17SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A171601Breast AdvancedOpen Active2019-01-14Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG-BR002Breast AdvancedOpen Active2018-07-19NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Pharm ODO-TE-B301Breast AdvancedOpen Active2018-07-26Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011106Breast NeoadjuvantOpen Active2018-12-10Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alliance Foundation Trials AFT-25Breast OtherOpen Active2018-02-07Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
NRG Oncology NRG-GI002GI OtherOpen Active2018-08-22NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
SWOG S1415CDCCDROpen Active2017-06-07SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2017-08-25Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-12-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2018-09-17ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
NRG Oncology NRG-LU002Lung NSCLC AdvancedOpen Active2018-06-21NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401SupportiveOpen Active2016-09-29Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
UNM 1701SupportiveOpen Active2017-10-12INST UNM 1701: A Qualitative Pilot Study to Evaluate the Unmet Needs of Patients Receiving Oral Oncolytic Therapy
WFU WF 97115SupportiveOpen Active2018-10-31WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer

CLINICAL_TRIAL_SITE

Trial #TypeStudy StatusStatus DateTitle
STUDY_NUMBERTYPE OF CANCERSTUDY STATUS1969-12-31STUDY_TITLE

Lovelace Medical Center-Saint Joseph Square

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1207Breast AdjuvantOpen Active2018-10-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2018-06-01SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A171601Breast AdvancedOpen Active2019-01-11Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG-BR002Breast AdvancedOpen Active2018-03-01NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Pharm CP-MGAH22-04Breast AdvancedOpen Active2018-02-16MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-01-11SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Alliance A021502GI Colorectal AdjuvantOpen Active2018-10-12Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1613GI Colorectal AdvancedOpen Active2018-02-23SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
SWOG S0820GI Colorectal PreventionOpen Active2018-07-27SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-15ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
INST 96144Ill DefinedOpen Active2015-07-28INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2017-08-25Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2018-09-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
NRG Oncology NRG-LU002Lung NSCLC AdvancedOpen Active2018-02-28NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-09SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-04-09SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400FLung SCLC AdvancedOpen Active2018-08-18SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2019-04-17ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
SWOG S1616Skin Melanoma AdvancedOpen Active2018-09-24SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401SupportiveOpen Active2016-09-17Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Lovelace Radiation Oncology

Trial #TypeStudy StatusStatus DateTitle
NSABP B-51Breast AdjuvantOpen Active2017-04-13NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
NRG-BR002Breast AdvancedOpen Active2018-03-01NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-10-10CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-01-11SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-15ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-02-21NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2017-06-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2017-06-07RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
NRG Oncology NRG-LU002Lung NSCLC AdvancedOpen Active2018-02-28NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial
WFU WF-1801SupportiveOpen Active2019-04-01Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Lovelace Respiratory Research Institute

Trial #TypeStudy StatusStatus DateTitle
LRRI #1054101Lung AncillaryOpen Active2001-03-01LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
INST UNM CR1801Multiple SitesOpen Active2018-09-04INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
Alliance A011401SupportiveOpen Active2017-11-08Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2017-01-26NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1207Breast AdjuvantOpen Active2018-10-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2018-06-01SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Pharm CP-MGAH22-04Breast AdvancedOpen Active2018-02-16MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Pharm ODO-TE-B301Breast AdvancedOpen Active2018-07-26Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
RTOG 1119Breast AdvancedOpen Active2016-10-06RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-08-21CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-03-27Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
SWOG S1613GI Colorectal AdvancedOpen Active2018-02-15SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
RTOG 0924GU Prostate AdvancedOpen Active2015-08-04RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
GOG 0263GYN Cervical AdjuvantOpen Active2011-02-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY005GYN OtherOpen Active2019-02-27NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2017-03-27ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2018-09-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-03-26SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400FLung SCLC AdvancedOpen Active2018-08-18SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2019-04-17ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401SupportiveOpen Active2016-12-16Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001SupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN E1Q11SupportiveOpen Active2018-04-18ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-10-20NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1207Breast AdjuvantOpen Active2018-10-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2018-06-01SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG-BR002Breast AdvancedOpen Active2017-05-04NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Pharm CP-MGAH22-04Breast AdvancedOpen Active2018-02-16MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Pharm ODO-TE-B301Breast AdvancedOpen Active2018-07-26Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011106Breast NeoadjuvantOpen Active2018-12-10Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
CCTG MA.39Breast NeoadjuvantOpen Active2018-11-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1613GI Colorectal AdvancedOpen Active2018-02-22SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Alliance A021602GI OtherOpen Active2018-10-18Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
NRG Oncology NRG-GI002GI OtherOpen Active2018-11-15NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Pharm PrTK03GU Prostate AdjuvantOpen Active2017-06-28Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-10-26ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NRG Oncology NRG-HN004Head And Neck AdvancedOpen Active2019-03-20NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Pharm 689-03Head And Neck AdvancedOpen Active2019-02-08Merck 689-03: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy forStage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Pharm INCB 18424-MA-GD-301Hematology Stem Cell TransplantOpen Active2019-01-29Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
INST 96144Ill DefinedOpen Active2014-12-09INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2017-08-25Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-17SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-04-17SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400FLung SCLC AdvancedOpen Active2018-08-18SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2019-04-17ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

NMOHC Gallup

Trial #TypeStudy StatusStatus DateTitle
INST 96144Ill DefinedOpen Active2018-06-18INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-08Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2018-06-01SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A171601Breast AdvancedOpen Active2019-01-11Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Pharm ODO-TE-B301Breast AdvancedOpen Active2018-07-26Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011106Breast NeoadjuvantOpen Active2018-12-10Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
SWOG S1415CDCCDROpen Active2017-06-07SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
SWOG S0820GI Colorectal PreventionOpen Active2017-11-29SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Pharm CA209901GU OtherOpen Active2017-08-30Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
INST 96144Ill DefinedOpen Active2013-06-04INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2017-08-25Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2018-09-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-03-26SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2019-04-17ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-04-17ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401SupportiveOpen Active2016-11-01Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2018-04-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2018-06-01SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A171601Breast AdvancedOpen Active2019-01-11Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011106Breast NeoadjuvantOpen Active2018-12-10Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
SWOG S1415CDCCDROpen Active2018-08-20SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
GOG 0263GYN Cervical AdjuvantOpen Active2018-06-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY012GYN Endometrial AdvancedOpen Active2019-04-08NRG Oncology NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
INST 96144Ill DefinedOpen Active2018-04-10INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2018-10-15SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2018-07-25Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-08-04Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2018-09-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-05SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-04-05SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2019-04-17ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Alliance A011401SupportiveOpen Active2018-04-19Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Pharm GCT1015-04GYN Cervical AdvancedOpen Active2019-02-20Genmab GCT1015-04: A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax -TF-ADC) Therapy in Previously Treated, Recurrent or Metastatic Cervical Cancer
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
NRG Oncology NRG-GY005GYN OtherOpen Active2019-02-08NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
NRG Oncology NRG-GY012GYN Endometrial AdvancedOpen Active2019-04-08NRG Oncology NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
NRG Oncology NRG-GY007GYN Ovarian AdvancedOpen Active2018-12-27NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
NRG-GY009GYN Ovarian AdvancedOpen Active2018-08-28NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubican and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicine/Bevacizumab in Platinum Resistant Ovarian Cancer
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
Diffusion 100-206Brain AdvancedOpen Active2018-05-22Diffusion Pharmaceuticals 100-206: Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
INST 1409Brain AdvancedOpen Active2016-03-09INST 1409: Single Center, Phase II Study of Whole Brain Radiation Using IMRT to Spare the Hippocampus while Delivering Differential Doses to Subclinical Sites versus Gross Disease for Treatment of Patients with Brain Metastases
ECOG-ACRIN EAF151Brain AdvancedOpen Active2017-08-30ECOG-ACRIN EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
NRG Oncology NRG-BN003Brain OtherOpen Active2017-10-20NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
NCCTG N0577Brain AdvancedOpen Active2017-12-18NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Dune Medical Devices CP-07-001Breast AdjuvantOpen Active2018-03-09Dune Medical Devices CP-07-001: MarginProbe System U.S. Post-Approval Study
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NSABP B-51Breast AdjuvantOpen Active2016-08-01NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
NRG Oncology NRG-BR005Breast AdjuvantOpen Active2017-07-18NRG Oncology NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2018-06-01SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
SWOG S1207Breast AdjuvantOpen Active2018-10-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance A171601Breast AdvancedOpen Active2019-01-11Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
NRG-BR002Breast AdvancedOpen Active2016-04-07NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-03-28Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Pharm CP-MGAH22-04Breast AdvancedOpen Active2017-11-07MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Novartis CBYL719X2402Breast AdvancedOpen Active2017-11-08Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, NoncomparativeStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment
Pharm SGNLVA-002Breast AdvancedOpen Active2018-02-20Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Pharm SGNLVA-001Breast AdvancedOpen Active2017-09-26Seattle Genetics, Inc. SGNLVA-001: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-LIVIA in Patients with LIV-1-Positive Metastatic Breast Cancer
Pharm ODO-TE-B301Breast AdvancedOpen Active2018-07-26Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
RTOG 1119Breast AdvancedOpen Active2016-10-06RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer
Pharm WO40181Breast AdvancedOpen Active2018-10-25Genentech WO40181: A Phase II, Multicenter, Randomized Study to Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer who Experienced Disease Recurrence or Progression During or After CDK4/6 Inhibitor Therapy
Alliance A011106Breast NeoadjuvantOpen Active2018-12-10Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
SWOG S1416Breast AdvancedOpen Active2018-08-10SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-09-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
UNM 1607Breast NeoadjuvantOpen Active2018-04-16INST UNM 1607: Monitoring of Breast Cancer Therapy Using High-speed MR Spectroscopic Imaging
SWOG S1706Breast NeoadjuvantOpen Active2019-01-11SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance A221405/ IBCSG 48-14/ BIG 8-13Breast OtherOpen Active2016-10-13Alliance A221405, IBCSG 48-14, BIG 8-13: POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer
ECOG-ACRIN EA1151Breast OtherOpen Active2018-08-31ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
Alliance Foundation Trials AFT-25Breast OtherOpen Active2018-02-07Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
SWOG S1415CDCCDROpen Active2017-06-07SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
Alliance A191402CDCCDROpen Active2018-01-24Alliance A191402CD: Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
UNM 1525Breast PreventionOpen Active2016-09-22INST UNM 1525: Breast cancer screening among medically underserved women in New Mexico: Comparing outcomes and LOwering recall rates with digital breast tomosynthesis (3D mammography) VErsus full-field digital (2D) mammography. The LOVE New Mexico study)
CIBMTR Protocol for a Research DatabaseEpidemiologicalOpen Active2017-06-29CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
WFU WF-30917CDCCDROpen Active2018-10-19WFU WF-30917CD: A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
UNM 1528EpidemiologicalOpen Active2016-04-01INST UNM 1528: Improving Colorectal Cancer Screening Rates in New Mexico Hispanics through Community Partnerships and Implementation Science
INST 1311EpidemiologicalOpen Active2013-02-04INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation
UNM 1702EpidemiologicalOpen Active2017-03-02INST UNM 1702: Occupational Tumors of Pulmonary Origin in United States (OcTOPUS)
UNM 1614EpidemiologicalOpen Active2017-04-23INST UNM 1614: Cost Measurement Feasibility for Low-Income Cancer Patients
UNM TCCPEpidemiologicalOpen Active2017-12-08INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
UNM 1803EpidemiologicalOpen Active2018-06-26INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
INST 1204GI Colorectal AncillaryOpen Active2012-05-22INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer
SWOG S1613GI Colorectal AdvancedOpen Active2018-02-15SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
Alliance A021502GI Colorectal AdjuvantOpen Active2018-10-12Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S0820GI Colorectal PreventionOpen Active2017-10-05SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
INST UNM 1809GI Colorectal PreventionOpen Active2018-12-27INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
Alliance A021602GI OtherOpen Active2018-10-18Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
INST 1009GI OtherOpen Active2010-11-17INST 1009: The Link Between Chronic Inflammation and Gastrointestinal Cancers (HTR Study)
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-08ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
SWOG S1815GI OtherOpen Active2019-04-05SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
NRG Oncology NRG-GI002GI OtherOpen Active2018-08-22NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
UNM 1603GI OtherOpen Active2016-11-30INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
Pharm CA209901GU OtherOpen Active2017-08-30Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Alliance A021501GI Pancreatic NeoadjuvantOpen Active2018-11-30Alliance A021501: Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
UNM 1805GU OtherOpen Active2019-01-08INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
Pharm GU14-188GU OtherOpen Active2018-02-07Hoosier Cancer Research Network GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm PrTK03GU Prostate AdjuvantOpen Active2017-06-28Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Pharm MK-3475-564-00GU RenalCell AdjuvantOpen Active2017-11-21Merck MK-3475-564-00: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Pharm 1205-201GU Prostate AdvancedOpen Active2018-08-01Constellation Pharmaceuticals 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-07-23RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-10-20GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Pharm GCT1015-04GYN Cervical AdvancedOpen Active2019-02-07Genmab GCT1015-04: A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax -TF-ADC) Therapy in Previously Treated, Recurrent or Metastatic Cervical Cancer
NRG Oncology NRG-GY006GYN Cervical AdvancedOpen Active2018-03-13NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA VaginalCancer
NRG Oncology NRG-GY012GYN Endometrial AdvancedOpen Active2019-04-08NRG Oncology NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
UNM 1509GYN OtherOpen Active2015-12-02INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG Oncology NRG-GY005GYN OtherOpen Active2019-02-08NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
NRG Oncology NRG-GY007GYN Ovarian AdvancedOpen Active2018-12-17NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
UNM 1419GYN Ovarian AdvancedOpen Active2018-11-12INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
NRG-GY009GYN Ovarian AdvancedOpen Active2018-08-28NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubican and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicine/Bevacizumab in Platinum Resistant Ovarian Cancer
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-12-14ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
INST 1008Head And Neck AdvancedOpen Active2014-12-11INST 1008: Expression and Epigenetic Silencing of MicroRNA for Predicting the Therapeutic Response and Prognosis of HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
RTOG 1008Head And Neck AdjuvantOpen Active2017-01-13RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
NRG Oncology NRG-HN004Head And Neck AdvancedOpen Active2019-03-20NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Pharm B9991016Head And Neck AdvancedOpen Active2017-10-25Pfizer B9991016: A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Pharm 689-03Head And Neck AdvancedOpen Active2019-01-11Merck 689-03: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy forStage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Pharm ImmunoGen 0601Hematology Acute LeukemiaOpen Active2018-05-07ImmunoGen 0601: A Phase I, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD-33-positive Acute Myeloid Leukemia
INST 0551CHematology Acute LeukemiaOpen Active2016-05-02INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia
SWOG S1608Hematology Lymphoma Non-HodgkinsOpen Active2018-10-08SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SWOG S1712Hematology Chronic LeukemiaOpen Active2019-02-21SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
UNM 1512CRHematology Acute LeukemiaOpen Active2018-05-23INST UNM 1512 (CHART REVIEW): A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2016-10-06ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
Alliance A061202Hematology MyelomaOpen Active2018-10-03Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
INST 1101Ill DefinedOpen Active2011-03-30INST 1101: Investigating Cancer-Related Information Processing of Patients and Family Members
Pharm INCB 18424-MA-GD-301Hematology Stem Cell TransplantOpen Active2019-01-29Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Pharm INCB 39110-209Hematology OtherOpen Active2018-05-17Incyte INCB 39110-209: An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
SWOG S1316Ill DefinedOpen Active2018-06-21SWOG S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
INST 1306Ill DefinedOpen Active2015-01-01INST 1306: Whole Genome Sequencing of Human Cancer Tissues
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2017-08-25Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
SWOG S1609Ill DefinedOpen Active2018-09-07SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2018-09-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG S1900ALung NSCLC AdvancedOpen Active2019-03-14SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-14SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
NRG Oncology NRG-LU002Lung NSCLC AdvancedOpen Active2017-12-06NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial
CALGB 30610Lung SCLC AdjuvantOpen Active2013-10-29CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
2903CLung OtherOpen Active2017-04-05INST 2903C: Lung Cancer Case Registry
SWOG S1400FLung SCLC AdvancedOpen Active2018-08-18SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
NRG Oncology NRG-CC003Lung SCLC AdjuvantOpen Active2019-01-09NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
SWOG S1616Skin Melanoma AdvancedOpen Active2018-09-24SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
Pharm TLPLDCSkin Melanoma AdvancedOpen Active2017-04-04Cancer Insight TLPLDC: A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (resected) Melanoma to Prevent Recurrence
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2019-04-17ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-JSolid Tumors OtherOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-MSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Pharm 2455-001Solid Tumors OtherOpen Active2018-03-06Kyowa Kirin Pharmaceutical 2455-001: Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
ECOG-ACRIN EAY131-Z1HSolid Tumors OtherOpen Active2018-07-08ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Pharm NLG-8021Solid Tumors OtherOpen Active2017-09-29NewLink Genetics NLG-8021: A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors
Pharm BXQ-350.AASolid Tumors OtherOpen Active2016-11-30Bexion BXQ-350.AA: Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas
Pharm RGX-104-001Solid Tumors OtherOpen Active2019-01-10Rgenix RGX-104-001: A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Pharm R3767-ONC-1613Solid Tumors OtherOpen Active2017-12-15Regeneron Pharmaceuticals R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
Pharm TRX518-003Solid Tumors OtherOpen Active2016-09-28Leap Therapeutics. Inc TRX518-003: A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
Pharm TPU-TAS-120-101Solid Tumors OtherOpen Active2017-07-10Taiho Oncology, Inc. TPU-TAS-120-101: A Dose-finding Phase 1 Study TAS-120 in Patients with Advanced Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Alliance Foundation Trials AFT-28SupportiveOpen Active2018-09-12Alliance Foundation Trials AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Alliance A011401SupportiveOpen Active2016-10-02Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN E1Q11SupportiveOpen Active2018-04-18ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
DCP-002SupportiveOpen Active2017-11-16NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
WFU WF 97115SupportiveOpen Active2017-07-06WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
NRG Oncology NRG-CC004SupportiveOpen Active2017-10-12NRG Oncology NRG-CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Women's Cancer and Surgical Care

Trial #TypeStudy StatusStatus DateTitle
INST 96144Ill DefinedOpen Active2018-06-13INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives